References

Global, Regional, and National Burden of Diabetes From 1990 to 2021, With Projections of Prevalence to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021

10.1016/s0140-6736(23)01301-6 · 2023 · External reference

The Many Faces of Diabetes: A Disease With Increasing Heterogeneity

10.1016/s0140-6736(13)62219-9 · 2014 · External reference

Novel Subgroups of Adult‐Onset Diabetes and Their Association With Outcomes: A Data‐Driven Cluster Analysis of Six Variables

10.1016/s2213-8587(18)30051-2 · 2018 · External reference

Precision Subclassification of Type 2 Diabetes: A Systematic Review

10.1038/s43856-023-00360-3 · 2023 · External reference

Clinical and Laboratory Characteristics of Novel Diabetes Subgroups: A Systematic Review and Meta‐Analysis

10.1038/s41598-025-22556-4 · 2025 · External reference

Novel Subgroups of Patients With Adult‐Onset Diabetes in Chinese and US Populations

10.1016/s2213-8587(18)30316-4 · 2019 · External reference

Risk of Diabetes‐Associated Diseases in Subgroups of Patients With Recent‐Onset Diabetes: A 5‐Year Follow‐Up Study

10.1016/s2213-8587(19)30187-1 · 2019 · External reference

Disease Progression and Treatment Response in Data‐Driven Subgroups of Type 2 Diabetes Compared With Models Based on Simple Clinical Features: An Analysis Using Clinical Trial Data

10.1016/s2213-8587(19)30087-7 · 2019 · External reference

Are the Different Diabetes Subgroups Correlated With All‐Cause, Cancer‐Related, and Cardiovascular‐Related Mortality?

10.1210/clinem/dgaa628 · 2020 · External reference

Novel Reclassification of Adult Diabetes Is Useful to Distinguish Stages of β‐Cell Function Linked to the Risk of Vascular Complications: The DOLCE Study From Northern Ukraine

10.3389/fgene.2021.637945 · 2021 · External reference

Assessing Reproducibility and Utility of Clustering of Patients With Type 2 Diabetes and Established CV Disease (SAVOR‐TIMI 53 Trial)

10.1371/journal.pone.0259372 · 2021 · External reference

Validation of the Classification for Type 2 Diabetes Into Five Subgroups: A Report From the ORIGIN Trial

10.1007/s00125-021-05567-4 · 2022 · External reference

Type 2 Diabetes Classification: A Data‐Driven Cluster Study of the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) Cohort

10.1136/bmjdrc-2021-002731 · 2022 · External reference

Factors Associated With Risk of Diabetic Complications in Novel Cluster‐Based Diabetes Subgroups: A Japanese Retrospective Cohort Study

10.3390/jcm9072083 · 2020 · External reference

Application of New International Classification of Adult‐Onset Diabetes in Chinese Inpatients With Diabetes Mellitus

10.1002/dmrr.3427 · 2021 · External reference

Clinical Characteristics and Risk of Diabetic Complications in Data‐Driven Clusters Among Type 2 Diabetes

10.3389/fendo.2021.617628 · 2021 · External reference

Subgroups of Patients With Young‐Onset Type 2 Diabetes in India Reveal Insulin Deficiency as a Major Driver

10.1007/s00125-021-05543-y · 2022 · External reference

Usefulness of Subclassification of Adult Diabetes Mellitus Among Inpatients in Japan

10.1111/jdi.13707 · 2022 · External reference

Roles of Plasma Leptin and Resistin in Novel Subgroups of Type 2 Diabetes Driven by Cluster Analysis

10.1186/s12944-022-01623-z · 2022 · External reference

Cardiorenal Risk Profiles Among Data‐Driven Type 2 Diabetes Sub‐Phenotypes: A Post‐Hoc Analysis of the China Health and Nutrition Survey

10.3389/fendo.2022.828403 · 2022 · External reference

Distribution and Characteristics of Newly Defined Subgroups of Type 2 Diabetes in Randomised Clinical Trials: Post Hoc Cluster Assignment Analysis of Over 12,000 Study Participants

10.1016/j.diabres.2022.110012 · 2022 · External reference

The Efficacy of Canagliflozin in Diabetes Subgroups Stratified by Data‐Driven Clustering or a Supervised Machine Learning Method: A Post Hoc Analysis of Canagliflozin Clinical Trial Data

10.1007/s00125-022-05748-9 · 2022 · External reference

Validation of the Swedish Diabetes Re‐Grouping Scheme in Adult‐Onset Diabetes in China

10.1210/clinem/dgaa524 · 2020 · External reference

Subtypes of Type 2 Diabetes and Their Association With Outcomes in Korean Adults—A Cluster Analysis of Community‐Based Prospective Cohort

10.1016/j.metabol.2023.155514 · 2023 · External reference

Secondary Analysis of Newly Diagnosed Type 2 Diabetes Subgroups and Treatment Responses in the MARCH Cohort

10.1016/j.dsx.2023.102936 · 2024 · External reference

Identifying Subtypes of Type 2 Diabetes Mellitus Based on Real‐World Electronic Medical Record Data in China

10.1016/j.diabres.2024.111872 · 2024 · External reference

Clinical Application of Cluster Analysis in Patients With Newly Diagnosed Type 2 Diabetes

10.1007/s42000-024-00593-4 · 2025 · External reference

Comorbidities and Mortality in Subgroups of Adults With Diabetes With up to 14 Years Follow‐Up: A Prospective Cohort Study in Sweden

10.1016/s2213-8587(25)00283-9 · 2026 · External reference

Randomized Open‐Label Trial of Semaglutide and Dapagliflozin in Patients With Type 2 Diabetes of Different Pathophysiology

10.1038/s42255-023-00943-3 · 2024 · External reference

Response to Insulin Glargine 100 U/mL Treatment in Newly Defined Subgroups of Type 2 Diabetes: Post Hoc Pooled Analysis of Insulin‐naïve Participants From Nine Randomised Clinical Trials

10.1016/j.pcd.2023.04.010 · 2023 · External reference

Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) With or Without Pre‐Prandial Insulin in Pre‐Treated Subphenotypes of Type 2 Diabetes: Insights From a Post Hoc Analysis

10.1007/s13300-024-01608-4 · 2024 · External reference

Treatment Responses to Basal Insulin Glargine 300 U/Ml and Glargine 100 U/Ml in Newly Defined Subphenotypes of Type 2 Diabetes: A Post Hoc Analysis of the EDITION 3 Randomized Clinical Trial

10.1111/dom.15336 · 2024 · External reference

Importance of Targeting Post‐Prandial Hyperglycaemia to Achieve HbA1c Goals in Insulin Glargine‐Treated Subphenotypes of Type 2 Diabetes

10.1111/dom.70231 · 2026 · External reference

A Web‐Based Application for Diabetes Subtyping: The DDZ Diabetes Cluster‐Tool

10.1007/s00592-024-02436-5 · 2025 · External reference

Subgroups of Adult‐Onset Diabetes: A Prospective Follow‐Up Study of Progression of Insulin Resistance and Deficiency and Association With Liver Steatosis and Fibrosis

10.1111/dom.70983 · 2026 · External reference

Disease Subtyping in Type 2 Diabetes: From Clusters to Clinical Translation

10.33137/utmj.v103i1.46160 · 2026 · External reference

Unveiling the Heterogeneity of T2DM: A Narrative Review of Clustering Algorithms in Stratifying Comorbidity and Complication Risk

10.1186/s40842-026-00273-9 · 2026 · External reference

Etiologies Underlying Subtypes of Long‐Standing Type 2 Diabetes

10.1371/journal.pone.0304036 · 2024 · External reference

SGLT2 Inhibitors and GLP‐1 Receptor Agonists: Established and Emerging Indications

10.1016/s0140-6736(21)00536-5 · 2021 · External reference

Beneficial Impact of Intensified Multifactorial Intervention on Risk of Stroke: Outcome of 21 Years of Follow‐Up in the Randomised Steno‐2 Study

10.1007/s00125-019-4920-3 · 2019 · External reference

Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes

10.2337/dci21-0034 · 2021 · External reference

The Case for Precision Medicine in the Prevention, Diagnosis, and Treatment of Cardiometabolic Diseases in Low‐Income and Middle‐Income Countries

10.1016/s2213-8587(23)00164-x · 2023 · External reference